Total medical devices industry M&A deals in Q1 2019 worth $7.77bn were announced in the US, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 67.2% over the previous quarter and a rise of 54.5% when compared with the last four-quarter average of $5.03bn.

The US held a 94.6% share of the global medical devices industry M&A deal value that totalled $8.22bn in Q1 2019.

In terms of deal activity, the US recorded 52 deals during Q1 2019, marking an increase of 21% over the previous quarter and a rise of 8.3% over the last four-quarter average.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US medical devices industry M&A deals in Q1 2019: Top deals

The top five medical devices industry M&A deals accounted for 98.5% of the overall value during Q1 2019.

The combined value of the top five medical devices industry M&A deals stood at $7.66bn, against the overall value of $7.77bn recorded for the quarter. The top announced medical devices industry M&A deal tracked by GlobalData in Q1 2019 was Johnson & Johnson’s $5.75bn acquisition of Auris Health.

In second place was the $1.14bn asset transaction with Thermo Fisher Scientific by PHC and in third place was Alcon Laboratories’ $285m acquisition of PowerVision.

The $260m asset transaction with Formulatrix by Qiagen and Pacira Pharmaceuticals’ acquisition of MyoScience for $220m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.